27 October 2023 ORYZON reports financial results and corporate updates for quarter ended September 30, 2023
10 October 2023 ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
3 October 2023 ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies
12 October 2023 Roth Capital Partners 2nd Healthcare Opportunities Conference The Yale Club, New York City NY United States
11-12 October 2023 Jefferies Inaugural Biotech CNS/Neuro Summit Jefferies Conference Center, New York City NY United States